Embed Size (px)
Citation preview
WORLD’S FIRST ONE WRIST ECG BANDIN $142B MARKET INVESTMENT OPPORTUNITY WITH 28X RETURN IN 3 YEARS
AND OTHER REVOLUTIONARY PRODUCTS FROM EUROPE’S FASTEST GROWING BIOTECH COMPANY
POWER PITCH
Planexta addressing the group of healthcare markets that will hit
$142 Billions by 2020
with unique and highly demanded technologies:
World’s first one-wrist ECG bandInstrumental Online Diagnostics
CardioCloud ServiceEndovenous Electric Welding
Planexta solutions are easily scalable, bring instant revenue, have numerous revenue streams.
World’s first one-wrist ECG bandand 5-product lineup of specialised
bands on its base
Endovenous Electric Welding technology
CardioCloudData Analysis Service
Health & Fitness Wearables3,8B market by 2020, CAGR 20%
Connected Healthcare 117B market by 2020 (Forbes), CAGR 36%
Endovenous Vascular Surgery (Potential 29B market by 2020)
Instrumental Online DiagnosticsTelemedicine Consulting Service
Planexta Technologies Markets
Electronic Health Records(21B market by 2020, CAGR 43%)
MARKET OPPORTUNITY
WHY WE WILL SUCCEED
Teamdriven by very successful entrepreneurs
and prominent medical professionals
Own R&D lab enables us to deliver super-fast results
Contract for 5 million units/month in sales till the end of 2016 with market access
company that has strong and relevant track record
Extensive experience in bringing products to European,
North American and Canadian markets
8 products in pipeline, 6 of them for both consumer and enterprise markets
Way ahead of the competitionLaunching with industry’s best offers
Own fund to attract large scale projects, such as United
Nations cardio-screening programs
Extremely high demand: pre-order for 50.000 wristband units from largest
CIS electronics dealer. Signed a number of partnership agreements with world’s leading
health companies and organisations
BUSINESS MODEL
Revenue sources: Customer acquisition: ECG Wristbands
Instrumental Online Diagnostics
CardioCloud Service
Endovenous Electro-welding
‣ Online & offline retail distributors
‣ White-label
‣ Publicity, networking and event participation
‣ Partnerships with telemedicine companies, healthcare organisations and funds
‣ Partnerships with insurance companies
‣ Partnerships with medical companies, organisations and funds
‣ Agreements with national and international healthcare funds and organisations‣ White-label
‣ Partnerships with medical and healthcare companies, organisations and funds
‣ Subscriptions (consumers)
‣ White-label
‣ Insurance companies
‣ Subscriptions (doctors)
‣ Subscriptions (medical companies)
‣ White-label
‣ Market access companies
‣ Market access companies
INVESTMENT
We need:
3,5M for 25% of equity.
How we will spend it:
‣ 1,2M for R&D Impulse Lab that will quadruple our effectiveness
‣ 300K for BizDev and Market Access dept., financial and legal services
‣ 1,75M to finalise development of the wristbands lineup
‣ 250K to launch in US and Canada
We propose:
‣ Clear exit strategy
‣ Clear 5 year P&L plan
‣ IPR capitalisation
VISION
HRV (Heart Rate Variability) analysis is an established method of monitoring for various health parameters: cardiovascular, respiratory, muscular, nervous and glandular systems, emotional state, immunity factors, stress, circadian rhythm, signs of ageing, etc. It might even save your life by alerting about upcoming heart attack. But in order to make accurate conclusions the measuring must be extremely precise and performed on a regular basis. That was limiting its usage to clinical environment.
Its benefits in full were available only to astronauts and pro-athletes.
We are bringing it to consumer market
VISION
BE AS HEALTHY AS AN ASTRONAUT!
Planexta Inc. created
world’s first one-wrist ECG band that performs HRV analysis with the same accuracy as hospital grade electrocardiograph. It measures >80 health parameters and helps you to get yourself into peak health state, both physical and mental.
Live long (+5 years on average) and prosper!
VISION
PRODUCTS: PLANEXTA ECG WRISTBAND LINEUP
World’s first one-wrist ECG band
Planexta ECG wristbands advantages
Unique technology, no direct competitor. We succeeded where many better funded companies was unable to deliver so far. Including Google.
Helps you to get yourself into peak health state, both physical and mental. It could even alert about conditions that have not yet manifested themselves,
including upcoming heart stroke.
PRODUCTS: PLANEXTA ECG WRISTBAND LINEUP
Planexta Active
World’s first one-wrist ECG bandLive to the max!
Status: prototype is ready. US patent pending.Working on design with STUCK, one of world’s top industrial design studios.
1st product lot TBD September 2016. Launch is planned for January 2017 at CES
PRODUCTS: PLANEXTA ECG WRISTBAND LINEUP
Planexta Sport Waterproof one-wrist ECG band + sports apps.
Train to the max!
Status: under development. 1st lot TBD September 2016.
PRODUCTS: PLANEXTA ECG WRISTBAND LINEUP
Planexta Care
Medical diagnostic instrument
Status: under development. 1st lot TBD September 2016.
PRODUCTS: PLANEXTA ECG WRISTBAND LINEUP
Planexta Care Pro
3-channel ECG + blood pressure sensor connected to medical infrastructure
Status: under development. 1st lot TBD September 2016.
PRODUCTS: PLANEXTA ECG WRISTBAND LINEUP
Planexta Home Care
6-channel wireless cardiograph for dynamic monitoring at home. 15% more accurate
than any competitors product.
Status: under development. 1st lot TBD September 2016.
PLANEXTA ECG WRISTBAND LINEUP: REVENUE MODEL
Customers: ‣ Consumers ‣ Health, fitness and medical companies ‣ Corporate wellness sector ‣ Healthcare funds and organisations
How do we make money: 30% profit margin of wristbands price (starts at $299) + $60 annual subscription fee for specialised apps.
Lifetime value of average customer: $1266
PLANEXTA ECG WRISTBAND LINEUP: TRACTION
▸ Secured 50.000 SKU order from largest CIS electronics dealer
▸ Partnered with: Beyond Nature Inc., market access company that made #7 most successful product launch in categoryGlobal Health Resolution FinanceGlobal Medic
▸ Huge interest from medical companies from all over the world
Alternative options have very limited application:
FitPal patch (not yet available) requires sticking it to the chest or stomach and positioned solely as a fitness gear.
AliveCor wristband for Apple Watch (awaiting FDA approval) requires pressing finger in order to receive data, so no continuous monitoring.
BioPac doesn’t make consumer devices.
All the rest (Samsung, Fitbit, etc.) measure not the electric impulses but simply pulse, which does not provide comparable data and precision.
PLANEXTA ECG WRISTBAND LINEUP: COMPETITORS
PLANEXTA ECG WRISTBAND LINEUP: MARKETING AND GROWTH STRATEGY
Planexta enters the market with the absolute best solutions in every sector.
We are going to win all relevant contests and competitions and get massive publicity: CES Awards, RedDot Award, MedTech Award, etc.
Besides traditional marketing channels we are working on cooperation with international healthcare organisations to solve the socially significant tasks.
PLANEXTA ECG WRISTBAND LINEUP: FINANCIALS
Pessimistic scenario
▸ Total customers: 691.800
▸ Total revenue: $208M
▸ Total expense: $114M
▸ EBITDA: $106M
Expected results:In 1 year the volume of sales will reach 5M/month.
Next year we plan to double sales due to US market expansion and launches in Europe, India and China.
Realistic scenario
▸ Total customers: 922.400
▸ Total revenue: $277M
▸ Total expense: $152M
▸ EBITDA: $141,6M
Optimistic scenario (excluding white-label and licensing strategy)
▸ Total customers: 1.153.000
▸ Total revenue: $346M
▸ Total expense: $190M
▸ EBITDA: $177M
3 years projection:
No more “How do you feel today?” questions.The doctor knows best
Planexta Instrumental Online Diagnostics advantages
Planexta ECG wristband measures 68 health parameters with the same accuracy as hospital grade electrocardiograph. Combined with telemedicine service, it enables doctor to monitor
patient’s health status remotely on a whole new level.
PRODUCTS: PLANEXTA INSTRUMENTAL ONLINE DIAGNOSTICS
PRODUCTS: PLANEXTA INSTRUMENTAL ONLINE DIAGNOSTICS
— So how am I doing, Doctor?
— I see your pain level decreased 42% and your stress index is 75% better!
Status: under development
PLANEXTA INSTRUMENTAL ONLINE DIAGNOSTICS: REVENUE MODEL
Customers: telemedicine companies
How do we make money: 30% profit margin of wristband price (starts at $299) + 5% of consultation cost ($2,5 per consultation).
Lifetime value of average customer: $1266
PLANEXTA INSTRUMENTAL ONLINE DIAGNOSTICS: COMPETITORS
Currently available options:
there are plenty of them.
But our solution takes the whole industry to the next level: ‣ It is wearable, this opens the opportunity of dynamic long-therm monitoring
and possibility to focus on prevention
‣ Delivers more complete analysis
‣ Has added benefit of continuous blood pressure measurement
PLANEXTA INSTRUMENTAL ONLINE DIAGNOSTICS: MARKETING AND GROWTH STRATEGY
‣ Territorial business development with gradual market penetration.
‣ Direct sales to doctors.
‣ Partnership programs with medical service providers and insurance companies.
PLANEXTA INSTRUMENTAL ONLINE DIAGNOSTICS: TRACTION
Partnered with:
‣ Global Health Resolution Finance
‣ Global Medic
‣ OVB Insurance Group
PLANEXTA INSTRUMENTAL ONLINE DIAGNOSTICS: FINANCIALS
Realistic scenario
▸ Total customers: 18500
▸ Total revenue: $23,5M
▸ Total expense: $3,85M
▸ EBITDA: $19,65M
3 years projection:
Making doctors 7X more effective. While saving them a ton of money
Planexta CardioCloudadvantages
There are no cloud solutions on the market. Currently clinics and doctors are buying
conventional stationary cardiographs for $6000-7000K that analyse data
with a built-in hardware.
We offer them tiny mobile cardiographs for $199 that deliver even more precise and much more comprehensive analysis
thanks to our CardioCloud service solution.
PRODUCTS: PLANEXTA CARDIOCLOUD
PRODUCTS: PLANEXTA CARDIOCLOUD
Status: under developmentExisting technology
+ =7X more
effective doctorwith mobile cardio-screening solution
PLANEXTA CARDIOCLOUD: REVENUE MODEL
Customers: doctors, hospitals, clinics, healthcare organisations.
How do we make money: $50 monthly fee + optional mobile electrocardiograph for $199.
Lifetime value of average customer: $12000
PLANEXTA CARDIOCLOUD: TRACTION
We already have a long queue of companies awaiting for this service with a total commitment for more than $1M (with a cost of sale <10%).
Partnered with:
‣ Global Health Resolution Finance
‣ Assmus Capital
PLANEXTA CARDIOCLOUD: COMPETITORS
Currently available solutions:
Biopac and other third-party software (Kubios, Corscience) are oriented on research, not business needs.
Other comparable options are pricey ($5000-$6000) and all have III-generation analytics capabilities, while we offer IV-generation (nosological & pre-nosological) diagnostics with 580 parameters.
PLANEXTA CARDIOCLOUD: FINANCIALS
Realistic scenario
▸ Total customers: 5000
▸ Total revenue: $210M
▸ Total expense: $42M
▸ EBITDA: $168M
3 years projection:
Now the surgeon knows exactly what he’s doing
Planexta Endovenous Electric Welding technology
Unlike it’s EVLA and RFA counterparts, electro-welding technology provides biofeedback during operation. And it’s extremely valuable for surgeons since they can monitor
intensity of their intervention.
30% Therapeutic Index increase. Greatly reduces operative and post-operative risks.
PRODUCTS: PLANEXTA ENDOVENOUS ELECTRIC WELDING
PRODUCTS: PLANEXTA ENDOVENOUS ELECTRIC WELDING
Status: working prototype already in use. Patent pending.
https://youtu.be/tRNXsRLIEQkWarning: explicit content
Endovenous laser surgery and RF ablation market size is 200M. And we are aiming to own 30% of it in 5 years.
But the market for procedure itself is 100X bigger.
This means huge potential for investment activity
PLANEXTA ENDOVENOUS ELECTRIC WELDING: INVESTMENT OPPORTUNITY
Problem
Currently clinics pay on average $30.000 for a laser device.
SolutionWe offer them much more cost-effective, “no-threshold" option: to lease an entire
“turn-key” solution and pay only a small percentage from every procedure cost. Planexta covers all aspects: technology, installation and doctor training.
Way to marketsPartnering with specialised medical companies that run medical device leasing business in US and Europe. For 60% of the cost of sales they will cover all necessary researches,
regulatory procedures, manufacture and marketing.
PLANEXTA ENDOVENOUS ELECTRIC WELDING: INVESTMENT OPPORTUNITY
PLANEXTA ENDOVENOUS ELECTRIC WELDING: REVENUE MODEL
Customers: doctors, clinics, hospitals.
How do we make money: 5% of procedure cost ($400-$2000)
Pricing: $20 on average
Lifetime value of average customer: $480.000
PLANEXTA ENDOVENOUS ELECTRIC WELDING: TRACTION
Partnered with:
‣ Global Health Resolution Finance Services
‣ Ozone Investment
PLANEXTA ENDOVENOUS ELECTRIC WELDING: MARKETING AND GROWTH STRATEGY
‣ Territorial business development with gradual market penetration.
‣ Direct sales to doctors, clinics, hospitals.
‣ Partnership programs with medical service providers and insurance companies.
PLANEXTA ENDOVENOUS ELECTRIC WELDING: FINANCIALS
Realistic scenario
▸ Total customers: 2000
▸ Total revenue: $60M
▸ Total expense: $50%
▸ EBITDA: $30M
3 years projection:
TEAM
Healthcare expertise:
Novartis, Genzyme, Merck Sharp & Dohme, Pfizer
Entrepreneurial expertise: Vector, pharmaceutical market access and development company that holds records in fast tracking national programs development for The World Bank, European Commission, Genzyme, MSD, Pfizer.
MGID.com, first native advertising marketplace ($30M annual turnover)
MedIT expertise: MAYO Clinic, John Hopkins University Clinic, Mount Sinai Hospital
Scientific expertise: microelectronics, system analysis, math methods, medical devices, sensor networks, social technologies
TEAM
CEO
Eugeny Nayshtetik, MIB, MM, MSOC, President Planexta Inc.
12 years of successful entrepreneurial experience in the field of life sciences. 14 years on top positions in Pfizer, Merck, Genzyme, Sanofi, Novartis.
A great number of achievements in medical market access sphere, including: ‣ The most fast tracking regional program development in Ukraine with further
inclusion into municipal budget for Genzyme ‣ The fastest market access with inclusion into national HIV program for Merck
Extensive experience in health technology assessment and objectivisation of pharmacoeconomics data on implementation of medical technologies.
International Business and Marketing Management graduate. PhD candidate in Social Technologies.
TEAM
R&D Leader
Tetiana Botsva
Unique experience with medical information technologies and medical software development. Deep knowledge in standardisation of medical technologies and business analysis.
9 years of hardware & software development experience in life sciences field.
Successful projects for MAYO clinic, John Hopkins University Clinic, Mount Sinai Hospital and number of clinics in Alaska (USA) SoftComputer Consultants (USA) in the background.
Physics, electronics and computer Systems graduate, PhD candidate
FINANCIALS: TOTAL FOR PLANEXTA INC.
Realistic scenario
▸ Total revenue: $570,5M
▸ EBITDA: $359,25M
Optimistic scenario (excluding white-label and licensing strategy)
▸ Total revenue: $639,5M
▸ EBITDA: $394,6M
3 years projection:
Pessimistic scenario
▸ Total revenue: $501,5M
▸ EBITDA: $323,6M
FINANCIALS: TOTAL FOR PLANEXTA INC.
3 years growth projection:
0
22.5
45
67.5
90
1Q ‘17 2Q ‘17 3Q ‘17 4Q ‘17 1Q '18 2Q '18 3Q '18 4Q ‘18 1Q '19 2Q ‘19 3Q '19 4Q '19
EBITDA, Millions
Contact person: Eugeny Nayshtetik
Mobile: +1 (323) 250-0679
Email: [email protected]
Skype: skabber
http://planexta.com
Community: fb.com/euromedicine
